Skip to main content
SpringerLink
Log in

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

Wachstumsfaktorblockade verlängert auch hier das Überleben

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Mok TS, Loong HH: A REVELation in non-small-cell lung cancer treatment? Lancet 2014;384(9944):640–2.

    Article  PubMed  Google Scholar 

Literatur

  • Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384(9944):665–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Klinische Pharmakologie, Universitätsklinikum Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Deutschland

    Klaus Mörike

Authors
  1. Klaus Mörike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mörike.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mörike, K. Wachstumsfaktorblockade verlängert auch hier das Überleben. Pneumo News 7, 24 (2015). https://doi.org/10.1007/s15033-015-0061-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0061-7

Search

Navigation